The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small ...